PHILADELPHIA, Feb. 2, 2026 /PRNewswire/ -- The Children's Brain Tumor Network (CBTN), a global research community advancing discovery for pediatric...
Brainomix 360 Stroke Next Generation has been awarded the prestigious Red Dot Design Award for excellence in usability and innovationAn...
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON,...
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02,...
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will...
XanaMIA trial fully enrolled with final results expected in November 2026SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited...
Mount Sinai and BPGbio scientists uncover novel molecular drivers from live brain samples that direct human brain structure and function...
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on...
Lake Oswego, Oregon--(Newsfile Corp. - February 2, 2026) - Functional Brands Inc. (NASDAQ: MEHA), parent company of Kirkman®, a trusted...
SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and...
NWEA MAP®, STAR®, aReading, AUTOreading, and WIST Results Reflect Gains in Reading and Language SkillsJACKSONVILLE, Fla., Jan. 29, 2026 /PRNewswire/...
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to...
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies...
Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and...
MIDDLETON, Wis., Jan. 28, 2026 /PRNewswire/ -- Natus Medical Incorporated announces the launch of the newest version of its industry-leading...
- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,...
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™...
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of...